✦ LIBER ✦

842 ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER INDUCES THE METABOLIC SYNDROME: IS IT PREVENTABLE?

✍ Scribed by J. Nobes; R.W. Laing; S.E.M. Langley

Book ID: 119620157
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 504 KB
Volume: 8
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(09)60830-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Metformin for the prevention of androgen

Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes

✍ Paul Cohen 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Increased Risk of Metabolic Syndrome, Di

Increased Risk of Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

✍ Dr. Polly E. Kintzel; Dr. Sandra L. Chase; Dr. Lisa M. Schultz; Dr. Timothy J. O 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB

LB23 Preventing bone loss during androge

LB23 Preventing bone loss during androgen-deprivation therapy for prostate cancer: The use of neridronate, a new third generation biphosphonate

✍ C. Magno; G. Anastasi; N. Morabito; A. Gaudio; A. Catalano; N. Frisina; D. Mello 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 219 KB

Mortality in Men Treated With Radiation

Mortality in Men Treated With Radiation Therapy and Androgen Deprivation for High-risk Prostate Cancer in the Modern Era is Driven by Non-prostate Cancer Deaths

✍ Tendulkar, R.D.; Hunter, G.K.; Reddy, C.A.; Stephans, K.L.; Ciezki, J.P.; Stephe 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 77 KB

351 PREVALENCE OF METABOLIC SYNDROME IN

351 PREVALENCE OF METABOLIC SYNDROME IN PROSTATE CANCER PATIENTS BEFORE AND AFTER 12 MONTHS OF ANDROGEN DEPRIVATION THERAPY: DATA FROM THE MULTICENTRE OBSERVATIONAL ANAMET STUDY

✍ Morote, Juan; Gómez-Caamaño, Antonio; Alvarez-Ossorio, José; Pesqueira, Daniel; 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 53 KB

Randomized, Double-Blinded, Placebo-Cont

Randomized, Double-Blinded, Placebo-Controlled, Trial of Risedronate for the Prevention of Bone Mineral Density Loss in Nonmetastatic Prostate Cancer Patients Receiving Radiation Therapy Plus Androgen Deprivation Therapy

✍ Choo, Richard; Lukka, Himu; Cheung, Patrick; Corbett, Tom; Briones-Urbina, Rosar 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 255 KB